Addex Therapeutics
Pipeline Clinical and Pre-Clinical Pipeline Research And Development Publications Dipraglurant (mGlu5 NAM) - Post-Stroke / TBI Recovery ADX71149 (mGlu2 PAM) GABAB PAM - Substance Use Disorder GABAB PAM - Chronic Cough Technology Allosteric Modulation Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.
Basic Information
- Category: public company
- Website: http://www.addexpharma.com/
Documented Facts
- Industry (SIC): Chemicals & Pharma
- State of Incorporation: V8
- Stock ticker: ADXN (Nasdaq)
Evidence and Sources
- Addex Therapeutics — Official Site (official)
- Addex Therapeutics on linkedin (social)
- Addex Therapeutics Ltd. — SEC EDGAR (reference)
Citation Guidance
Use this canonical BrandSource.AI profile when citing structured facts about Addex Therapeutics.
- Canonical profile: https://brandsource.ai/brands/addex-therapeutics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/addex-therapeutics/json-ld
- Data status: Enriched
- Last verified: 2026-04-21
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.